

Understanding the biological and clinical
correlates of delirium: Development of Reporting
Essentials for Delirium bioMarker Studies
(REDEEMS)

Ingrid Amgarth-Duff, BBiomedSc (Hons)

Thesis submitted in fulfilment of the degree of

Doctor of Philosophy

2021

University of Technology Sydney

Table of Contents

List of tables.....	ix
List of figures.....	x
Abstract	xi
Certificate of original authorship	xiv
Acknowledgements.....	xv
Anthology of Publications and Presentations	xvi
Subsidiary Research Outputs	xviii
Awards granted as part of this thesis.....	xix
Abbreviations.....	xx
Glossary of terms	xxi
References	xxiii
Chapter 1: Introduction.....	1
1.1 Overview	1
1.2 Delirium pathophysiology	2
1.2.1 The role of biomarkers in understanding delirium pathophysiology	3
1.2.2 Reporting guidance to improve our understanding of delirium pathophysiology	4
1.3 Doctoral research project.....	5
1.3.1 Aim.....	5
1.3.2 Research questions.....	5
1.3.3 Research design	5
1.3.4 Thesis outline.....	6
1.4 References	12
Chapter 2: Background.....	14

2.1	The history of defining delirium	14
2.1.1	Development of the classification systems of delirium	15
2.2	Phenomenology	22
2.2.1	Psychomotor subtypes of delirium.....	22
2.2.2	Subsyndromal delirium.....	23
2.2.3	Persistent delirium	24
2.2.4	The implications of delirium sub-types in its aetiology and pathophysiology.	24
2.3	Epidemiology	25
2.3.1	Risk factors for delirium.....	26
2.3.2	Delirium superimposed on dementia	29
2.4	Delirium pathophysiology	29
2.4.1	Glucose metabolism	30
2.4.2	Neuronal ageing	30
2.4.3	Oxidative stress	30
2.4.4	Neurotransmitter disruption	31
2.4.5	Circadian cycle dysregulation	31
2.4.6	Neuroendocrine dysregulation.....	32
2.4.7	Neuro-inflammation	32
2.4.8	Systems Integration Hypothesis	32
2.5	Delirium prevention.....	33
2.5.1	Multicomponent interventions	33
2.6	Delirium treatment	34
2.6.1	Pharmacological interventions	34
2.7	Summary	37
2.8	References	38

Chapter 3: A systematic review of the overlap of biomarkers in delirium and advanced cancer-related syndromes	45
3.1 Chapter preface	45
3.2 Introduction.....	46
3.2.1 Aim.....	47
3.3 Methods	47
3.3.1 Design	47
3.3.2 Search method	47
3.3.3 Inclusion and exclusion criteria	48
3.3.4 Study selection, data extraction and management.....	48
3.3.5 Quality assessment.....	49
3.3.6 Data synthesis.....	49
3.4 Results.....	50
3.4.1 Study characteristics.....	52
3.4.2 Delirium and advanced cancer biomarkers	96
3.4.3 Quality assessment.....	132
3.5 Discussion	135
3.5.1 Strengths and limitations.....	139
3.6 Conclusion	139
3.7 References	140

Chapter 4: Development of Reporting Essentials for DELirium bioMarker

Studies (REDEEMS): A Delphi study and consensus meeting	154
4.1 Chapter preface	154
4.2 Introduction.....	156
4.2.1 Background to reporting guidelines	156

4.2.2	Need for reporting guidelines for delirium biomarker studies.....	157
4.2.3	Background to the Delphi method	158
4.2.4	The Classical Delphi	158
4.2.5	Reliability, validity and trustworthiness	160
4.2.6	Aim.....	161
4.2.7	Objectives	161
4.3	Methods	162
4.3.1	Framework used for the REDEEMS guidelines	162
4.3.2	Study design	164
4.3.3	Rationale for selecting the Delphi method.....	164
4.3.4	Survey preparation	165
4.3.5	Participant selection and recruitment.....	165
4.3.6	Data collection.....	166
4.3.7	Data analysis.....	168
4.3.8	Recruitment of the second expert panel.....	170
4.3.9	Consensus meeting preparation.....	170
4.4	Ethical considerations	171
4.4.1	Ethical approval	171
4.4.2	Considerations for participants	171
4.4.3	Confidentiality	172
4.4.4	Data management and storage	172
4.5	Results	172
4.5.1	Participants.....	172
4.5.2	Consensus.....	175
4.5.3	Participants.....	185
4.5.4	Delphi items discussed in the consensus meeting	186

4.5.5	The final REDEEMS checklist.....	194
4.6	Discussion	198
4.6.1	Limitations and strengths	199
4.6.2	Implications for future research and practice	200
4.7	Summary	201
4.8	References	202

Chapter 5: Delirium Researchers’ Perspectives of the Challenges in Delirium

	Biomarker Research: A Qualitative study.....	206
5.1	Chapter preface	206
5.2	Introduction.....	207
5.3	Aim	208
5.4	Objectives	208
5.5	Methods	208
5.5.1	Study design	208
5.5.2	Participants.....	208
5.5.3	Recruitment.....	209
5.5.4	Data collection.....	210
5.5.5	Data analysis.....	212
5.5.6	Trustworthiness of the data (credibility, transferability, dependability, and confirmability)	213
5.6	Ethical considerations	214
5.6.1	Ethical approval	214
5.6.2	Confidentiality and informed consent.....	214
5.6.3	Data management and storage	214
5.7	Findings	215

5.7.1	Practical and scientific challenges of delirium biomarker research: stagnation versus ways driving improved methods and reporting	217
5.7.2	Valuing delirium research through investment and collaboration	235
5.8	Discussion	239
5.9	Strengths and limitations	245
5.10	Conclusion	246
5.11	References	247
Chapter 6:	REDEEMS Explanation and Elaboration document.....	250
6.1	Chapter Preface	250
6.2	Introduction.....	251
6.2.1	Development of the REDEEMS guideline	251
6.2.2	How to use the REDEEMS guideline	252
6.2.3	How to use the E&E document.....	253
6.3	REDEEMS guideline items.....	253
6.4	Concluding remarks	268
6.5	References	270
Chapter 7:	Conclusion and Recommendations	274
7.1	Summary of findings	274
7.1.1	Research question 1: What is the overlap in the biomarkers in delirium and advanced cancer-related syndromes?.....	274
7.1.2	Research question 2: What are the critical elements of high quality conduct and reporting for delirium biomarker studies?	275
7.1.3	Research question 3: What are the key methodological challenges in conducting delirium biomarker research?	276
7.2	Recommendations of this doctoral research	283

7.3	Strengths and limitations	286
7.3.1	Strengths	286
7.3.2	Limitations	286
7.4	Summary	287
7.5	References	288

List of tables

TABLE 1.1 THESIS NAVIGATION TOOL	10
TABLE 1.2 APPENDICES CONTENT AND NAVIGATION	11
TABLE 2.1 HISTORY OF THE EVOLVING DSM DIAGNOSTIC CRITERIA FOR DELIRIUM (1980-2013) COMPARED TO CURRENT ICD DIAGNOSTIC CRITERIA	18
TABLE 2.2 RISK FACTORS FOR DELIRIUM FROM VALIDATED PREDICTIVE MODELS ^{8,49-51}	27
TABLE 2.3 DELIRIUM PREVALENCE, INCIDENCE AND OCCURRENCE ACCORDING TO SYSTEMATIC REVIEW DATA	28
TABLE 3.1 PARTICIPANT CHARACTERISTICS- DELIRIUM STUDIES	53
TABLE 3.2 PARTICIPANT CHARACTERISTICS- CANCER STUDIES.....	69
TABLE 3.3 CHARACTERISTICS OF ASSAYS AND MAIN FINDINGS OF INCLUDED DELIRIUM STUDIES* ..	98
TABLE 3.4 CHARACTERISTICS OF ASSAYS AND MAIN FINDINGS OF INCLUDED CANCER STUDIES* ...	114
TABLE 4.1 OTHER REPORTING GUIDELINES RELEVANT TO BIOMARKER STUDIES	158
TABLE 4.2 STAGES OF DEVELOPMENT FOR THE REDEEMS CHECKLIST ADAPTED FROM MOHER ET AL (2010).....	163
TABLE 4.3 DEMOGRAPHIC CHARACTERISTICS OF DELPHI PARTICIPANTS (N=32)	174
TABLE 4.4 SUMMARY OF RATINGS FOR ITEMS THAT REACHED A $\geq 70\%$ CONSENSUS AFTER THREE DELPHI ROUNDS*	178
TABLE 4.5 SUMMARY OF RATINGS FOR ITEMS THAT DID NOT REACH A CONSENSUS AFTER THREE ROUNDS OF DELPHI*	182
TABLE 4.6 THE PRELIMINARY LIST OF RECOMMENDATIONS FOR REPORTING DELIRIUM BIOMARKER STUDIES, FOLLOWING THE DELPHI*	183
TABLE 4.7 CONSENSUS MEETING PARTICIPANT CHARACTERISTICS (N=12).....	186
TABLE 4.8 PARTICIPANTS' VOTES FOR INCLUSION/EXCLUSION OF ITEMS.....	188
TABLE 4.9 PARTICIPANT WORDING SUGGESTIONS IN OPEN-TEXT FORM	191
TABLE 4.10 FINAL REDEEMS CHECKLIST ITEMS.....	195
TABLE 4.11 COMPARISON OF THE REDEEMS CHECKLIST AGAINST CURRENT REPORTING GUIDELINES RELEVANT TO BIOMARKER STUDIES.....	196
TABLE 5.1 PARTICIPANT DEMOGRAPHICS (N=15).....	216

List of figures

FIGURE 1.1 OUTLINE OF THE THREE STUDIES IN THIS DOCTORAL RESEARCH PROJECT	7
FIGURE 3.1 PRISMA FLOW DIAGRAM OF SEARCH RESULTS.....	51
FIGURE 3.2 CONCEPTUAL MODEL ILLUSTRATING THE ‘TRUE OVERLAP’ OF DELIRIUM AND ADVANCED CANCER BIOMARKER STUDIES.....	97
FIGURE 3.3 QUALITY ASSESSMENT GRAPH OF THE ASSAY PROCEDURES: AUTHOR'S JUDGEMENTS ABOUT EACH ASSAY DOMAIN OF THE REMARK CHECKLIST, PRESENTED AS PERCENTAGES ACROSS STUDIES.....	133
FIGURE 3.4 QUALITY ASSESSMENT GRAPH OF THE DELIRIUM STUDIES, PRESENTED AS PERCENTAGES ACROSS STUDIES	134
FIGURE 4.1 THE REDEEMS GUIDELINE DEVELOPMENT PROCESS EMPLOYED IN STUDY 2, HIGHLIGHTING THE STAGES REPORTED IN THIS CHAPTER	155
FIGURE 4.2 FLOW CHART ILLUSTRATING THE THREE-STAGE DELPHI PROCESS, INFORMED BY A PRIOR SYSTEMATIC REVIEW	176
FIGURE 7.1 PROPOSED MODEL OF THE INTER-RELATED KEY CHALLENGES, COMPLEXITIES, AND CONSIDERATIONS IN DELIRIUM BIOMARKER RESEARCH.....	278
FIGURE 7.2 SUMMARY OF THE DOCTORAL RESEARCH PROJECT	285

Abstract

Background

Delirium is a common, serious and complex neurocognitive condition that is associated with negative impacts for both the person with delirium and their family/carers. Despite the significant burden, the pathophysiology of delirium remains unclear. To improve our understanding of delirium pathophysiology, robust delirium biomarker studies with optimal reporting are urgently needed to ensure each of these studies contribute to accelerate our knowledge.

Aim

To evaluate and optimize the methodological approaches in research evaluating biological and clinical correlates of delirium and underlying conditions.

Design

A multiple methods project, involving three discreet but inter-related studies conducted over three stages.

Methods

Study 1 was a systematic review of the overlap of delirium and advanced cancer-related syndrome biomarkers as an ‘exemplar’ of the potential for interaction between the underlying condition and delirium; Study 2a was a three-stage modified Delphi study with delirium researchers and study 2b was a follow-up consensus meeting to generate a reporting guideline specific to delirium biomarker studies (REDEEMS). Study 3 comprised a series of semi-structured interviews which sought delirium researchers’ perceptions of the key challenges of conducting delirium biomarker studies.

Results

The systematic review identified considerable overlap of delirium and advanced cancer biomarkers, with 41 biomarkers that had been studied in relation to both delirium and either an advanced cancer-related syndrome or prognosis. It also revealed a significant gap in the consistency and reporting of delirium biomarker studies. Considering this unexpected finding of poor quality, a drive to improve the methods of reporting delirium biomarker studies was warranted. The international Delphi study and consensus meeting (study 2) revealed a total of nine items which were deemed critical elements by delirium researchers for inclusion in the REDEEMS guideline. Finally, the third qualitative study identified a range of factors that contribute to the challenges and overall quality of delirium biomarker research. Delirium researchers concurred that delirium biomarker research is both an extremely difficult and complex field, and that the quality of reporting delirium biomarker research is poor, which contribute to lack of progress in scientific understanding. Analysis revealed two major themes and ten sub-themes, outlining key considerations to advance the field of delirium biomarker research. The major themes were: 1) Practical and scientific challenges of delirium biomarker research: stagnation versus driving improved methods and reporting; and 2) Valuing delirium research through investment and collaboration.

Conclusion

The REDEEMS guideline is the first reporting guideline specific for delirium biomarker studies aligned with impacts of reporting guidelines in other research methods. It aims to guide improvements in consistency and transparency of reporting future biomarker studies in delirium, conceivably permitting accurate replication and synthesis, and improving scientific rigor in the field. A collaborative effort to increase

awareness of, and improve research funding for delirium is needed, along with increased education and training in delirium biomarker methodology. These advancements will lead to significant improvement of our understanding of delirium pathophysiology and ultimately improve outcomes for people with delirium.

Certificate of original authorship

I, Ingrid Kathrine Viktoria Amgarth-Duff declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy in faculty of health at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis. This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program.

Signature of candidate:

Production Note:

Signature removed prior to publication.

Date: 06.07.21

Acknowledgements

First and foremost, I would like to thank my family, my everything. To my husband Joseph, who planted the seed in my head that I could undertake a PhD. Thank you for your love and unwavering encouragement, and the resolute belief and confidence you have in me. Thank you for being the best dad to our son Otto who was born amid completing this PhD.

To my parents, Lena and Lauchie, and my brother, Kristian- thank you for the love and support you have provided me throughout my life, it has meant more than you will ever know. To my parents-in-law, Marisa and Joe- thank you for welcoming me into your family and supporting me on every level. To our beautiful Otto- thank you for being you. Words cannot even begin to describe the love we have for you. Lastly, my dog Alfie, for being the best distraction from my PhD.

I am forever indebted to my principal supervisor, Professor Meera Agar, and my co-supervisors Associate Professor Annmarie Hosie and Associate Professor Gideon Caplan. Thank you for your expertise, commitment, kindness and patience whilst helping grow my confidence during this journey. The hours you spent with me and the back and forth discussions to ensure we had it right, are much appreciated. Your love and dedication to delirium research is more than evident.

My heartfelt thanks to all participants who committed a significant amount of their time to this project, sharing their stories and experiences. Their novel thoughts on delirium pathophysiology will continue to inform my future research.

Last, but not least, to my IMPACCT colleagues (and IMPACCTFUL isolation getting us through the COVID-19 lock down), and my amazing friends in and outside of my PhD world. Thank you for supporting me along this journey by offering advice, sanity, and delicious snacks. A special thanks to my friend Ash Hendriks for helping with the design of the figures in this thesis.

Funding from the Australasian Delirium Association is gratefully acknowledged.

Anthology of Publications and Presentations

Peer-reviewed journal publications associated with this thesis

Amgarth-Duff, I., Hosie, AM., Caplan, G., Agar, M. A systematic review of the overlap of fluid biomarkers in delirium and advanced cancer-related syndromes. *BMC Psychiatry*. 2020; 20:182.

Amgarth-Duff, I., Hosie, AM., Caplan, G., Agar, M. Toward Best Practice Methods for Delirium Biomarker Studies: An International Modified Delphi Study. *International Journal of Geriatric Psychiatry*. 2020;35:737-748.

Amgarth-Duff, I., Hosie, AM., Caplan, G., Agar, M. Delirium researchers' perspectives of the challenges in delirium biomarker research: A qualitative study. *PLOS ONE*. 2021;16:4:e0243254.

Amgarth-Duff, I., Hosie, AM., Caplan, G., Agar, M. Development of Reporting Essentials for Delirium biomarker Studies (REDEEMS): Elaboration and Explanation. *Journal of the Academy of Consultation-Liaison Psychiatry*. 2021 (Under review)

Conference presentations as part of this thesis

Amgarth-Duff, I., Hosie, A., Caplan, G., Agar, M. (2018). A Systematic Review of Biomarkers in Delirium and Advanced Cancer. *Palliative Care Nurses Australia Biennial Conference, Brisbane, Australia, 20-21st May, 2018*. Oral presentation.

Amgarth-Duff, I., Hosie, A., Caplan, G., Agar, M. (2018). A Systematic Review of Biomarkers in Delirium and Advanced Cancer. *Palliative Care Nurses Australia Biennial Conference, Brisbane, Australia, 20-21st May, 2018*. Poster presentation.

Amgarth-Duff, I., Hosie, A., Caplan, G., Agar, M. (2018). A Systematic Review of Biomarkers in Delirium and Advanced Cancer. *American Delirium Society Annual Conference, San Francisco, USA, 10-12th June, 2018.* Poster presentation.

Amgarth-Duff, I., Hosie, A., Caplan, G., Agar, M. (2019). Defining Methodological and Best Practice for Studies of Biological and Clinical Correlates of Delirium– An International Modified Delphi Study. *American Delirium Society Annual Conference, Boston, USA, 16-18th June, 2019.* Poster presentation.

Amgarth-Duff, I., Hosie, A., Caplan, G., Agar, M. (2019). Defining Methodological and Best Practice for Studies of Biological and Clinical Correlates of Delirium – An International Modified Delphi Study. *European Delirium Association Annual Conference, Edinburgh, Scotland, 5-6th September, 2019.* Poster presentation.

Amgarth-Duff, I., Hosie, A., Caplan, G., Agar, M. (2019). Defining Methodological and Best Practice for Delirium Biomarker Studies. *European Delirium Association Annual Conference, Edinburgh, Scotland, 5-6th September, 2019.* Poster presentation.

Other presentations

Amgarth-Duff, I. (2019). Defining Methodological and Best Practice for Studies of Biological and Clinical Correlates of Delirium in Advanced Cancer – An International Modified Delphi Study, *IMPACCT Summer School*, University of Technology Sydney

Amgarth-Duff, I. (2019). A Systematic Review of Biomarkers in Delirium and Advanced Cancer-Related Syndromes, *IMPACCT Summer School*, University of Technology Sydney

Subsidiary Research Outputs

Peer-reviewed journal articles

Hosie, A., Siddiqi, N., Featherstone, I., Johnson, M., Lawlor, P.G., Bush, S.H., **Amgarth-Duff, I.**, Edwards, L., Phillips, J., and Agar, M. (2019). Inclusion, characteristics and outcomes of people requiring palliative care in studies of non-pharmacological interventions for delirium: A systematic review. *Palliative Medicine*, 33(8).

Book chapter

Hosie, AM., **Amgarth-Duff, I.**, Agar, M. (2017). Delirium and Terminal Agitation. MacLeod, R & Van Den Block, L (Eds.) In *Textbook of palliative care*. Sydney, Australia: Springer.

Awards granted as part of this thesis

1. UTS Doctoral Scholarship, University of Technology Sydney (2017-2020)
2. Prince of Wales Hospital Research Award for Delirium Research (2017-2020)
3. Australasian Delirium Association Research Award (2019)

Abbreviations

ADA	Australasian Delirium Association
ADS	American Delirium Society
APA	American Psychiatric Association
BRISQ	Biospecimen Reporting for Improved Study Quality
CAM	Confusion Assessment Method
CNS	Central nervous system
CONSORT	CONsolidated Standards Of Reporting Trials
CSF	Cerebrospinal fluid
DSD	Delirium superimposed on dementia
DSM	Diagnostic and Statistical Manual of Mental Disorders
E&E	Explanation and Elaboration document
EDA	European Delirium Association
ELISA	Enzyme-Linked Immunosorbent Assay
EQUATOR	Enhancing the QUALity and Transparency Of Reporting
HREC	Human Research Ethics Committee
ICD-10	International Classification of Disease, edition 10
LP	Lumbar puncture
N/A	Not applicable
POD	Post-operative delirium
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT	Randomised Controlled Trial
REDEEMS	Reporting Essentials for DELirium bioMarker Studies
REMARK	Reporting rEcommendations for tumour MARKer prognostic studies
SAGES	Successful Aging after Elective Surgery
SSD	Subsyndromal delirium
STARD	Standards for Reporting of Diagnostic Accuracy Studies
STROBE	Strengthening the Reporting of Observational Studies in Epidemiology
UK	United Kingdom
USA	United States of America

Glossary of terms

Advanced cancer	Inclusive of stage III cancer (locally advanced with spread to nearby tissues or lymph nodes) and Stage IV cancer (metastatic disease). ¹
Anorexia cachexia	A complex metabolic syndrome of involuntary weight loss associated with cancer and some other palliative conditions. ²
Biomarker	A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. ³
Cancer prognosis	The likely outcome or course of the disease; the chance of recovery or recurrence. Cancer prognosis is assessed by cancer-specific survival, overall survival, progression free survival or relative survival. ⁴
Cancer-related cognitive impairment	Cognitive impairment that is commonly experienced by cancer patients and those in remission. The cognitive domains most commonly affected are memory, concentration, information processing speed and executive function. ⁵
Cancer-related fatigue	A distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning. ⁶
Cancer-related pain	An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. ⁷
Classical Delphi Methodology	A research methodology with an aim to achieve consensus on a research question, using an expert panel, in an iterative and controlled survey process. ⁸
Delirium	A neurocognitive disorder, characterised by acute disturbance to attention, awareness and cognition, affecting memory, language, visuospatial ability, orientation and perception.
e-Delphi	A Delphi research method that involves the distribution of a survey electronically to panellists via email.
Hyperactive delirium	Delirium subtype where the patient has an increased level of psychomotor activity. There may also be lability of mood, agitation and resistance to medical care. ⁹
Hypoactive delirium	Delirium subtype where the patient has a decreased level of psychomotor activity, along a continuum from lethargy to stupor. ⁹
Incidence	The occurrence of new cases of a disease in a population over a specified period of time. ¹⁰
Mixed delirium	Delirium subtype where the patient has either a normal or fluctuating level of psychomotor activity. ⁹
Modified Delphi	Describes any methodological variation of the Classical Delphi method described by Dalkey and Helmer (1962). ¹¹
Morbidity	Non-fatal event.
Mortality	Fatal event/death.
Multiple methods	The use of two or more research methods in one research project. ¹²
Persistent delirium	Full syndromal delirium at the time of admission (or shortly after admission) that continues to meet the criteria for delirium at the time of discharge or beyond. ¹³
Prevalence	The proportion of a persons in a population who have a particular disease or attribute at a specified point in time or over a specified period of time. ¹⁰
Point prevalence	The proportion of persons with a particular disease or attribute at a particular point in time (on a particular date). ¹⁰

Prodromal delirium	Manifestation of symptoms such as changes to concentration, mood (irritability, anxiety, depression), sleep patterns (including vivid dreaming), cognition (e.g. disorientation), tiredness or noise sensitivity, that can occur in the hours, days or weeks prior to full syndromal delirium. ¹⁴
Qualitative research	A means for exploring and understanding the meaning of individuals or groups ascribed to a social or human problem. ¹⁵
Quantitative research	A means for testing objective theories by examining the relationship among variables. ¹⁵
Reporting guideline	A checklist, flow diagram, or explicit text to guide authors in reporting a specific type of research, developed using explicit methodology. ¹⁶
Sickness behaviour	The coordinated set of behavioural changes that develop in sick individuals during the course of an infection. Sickness behavior is also seen in other illness including cancer. ^{17,18}
Sub-syndromal delirium	Presence of one or more symptoms of delirium, where the patient does not meet the criteria for delirium. ¹⁹ Termed 'attenuated delirium syndrome' by the DSM-5. ⁹

References

1. Cancer Institute NSW. Stages of Cancer. Accessed 19 July 2018.
2. CareSearch. Cachexia Anorexia Syndrome 2017; <https://www.caresearch.com.au/caresearch/tabid/183/Default.aspx>. Accessed July 19, 2018.
3. National Cancer Institute. NCI Dictionary of Cancer Terms. <https://www.cancer.gov/publications/dictionaries/cancer-terms/?CdrID=45618>. Accessed November 28, 2017.
4. National Cancer Institute. Understanding Cancer Prognosis 2018; <https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis>. Assessed November 28, 2017.
5. Bray V, Dhillon H, Vardy J. Cancer-related cognitive impairment in adult cancer survivors: A review of the literature 2017; <https://cancerforum.org.au/forum/2017/march/cancer-related-cognitive-impairment-in-adult-cancer-survivors-a-review-of-the-literature/>.
6. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. *Clinical Oncology*. 2014;11(10):597.
7. International Association for the Study of Pain. IASP Terminology. 2017; <https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698&navItemNumber=576> - Pain.
8. Keeney S, McKenna H, Hasson F. *The Delphi technique in nursing and health research*. John Wiley & Sons; 2011.
9. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)*. Arlington, VA: American Psychiatric Publisher; 2013.
10. Centers for Disease Control and Prevention. Lesson 3: Measures of Risk. 2012; <https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section2.html>. Accessed 27 July 2020.
11. Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. *Management Science*. 1963;9(3):458-467.
12. Brannen J. *Mixing methods: Qualitative and Quantitative research*. Routledge; 2017.
13. Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. *Age and Ageing*. 2009;38(1):19-26.

14. Gupta N, de Jonghe J, Schieveld J, Leonard M, Meagher D. Delirium phenomenology: What can we learn from the symptoms of delirium? *Journal of Psychosomatic Research*. 2008;65(3):215-222.
15. Creswell JW, Creswell JD. *Research design: Qualitative, quantitative, and mixed methods approaches*. SAGE Publications; 2017.
16. Moher D, Weeks L, Ocampo M, et al. Describing reporting guidelines for health research: a systematic review. *Journal of Clinical Epidemiology*. 2011;64(7):718-742.
17. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. *European Journal of Pharmacology*. 2004;500(1-3):399-411.
18. Dantzer R. Cytokine-induced sickness behavior: where do we stand? *Brain, Behavior, and Immunity*. 2001;15(1):7-24.
19. Cole MG, Ciampi A, Belzile E, Dubuc-Sarrasin M. Subsyndromal delirium in older people: a systematic review of frequency, risk factors, course and outcomes. *International Journal of Geriatric Psychiatry*. 2013;11(4):534-543.